ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0851

Diagnostic Ultrasound Enthesitis Tool (DUET) for Psoriatic Arthritis: The Distribution of Elementary Lesions Is Influenced by Site

Lihi Eder1, Ricardo Acayaba de Toledo2, Fahmeen Afgani3, Catherine Bakewell4, Philippe Carron5, Basant Elnady6, Amir Haddad7, Arthur Kavanaugh8, Arnon Katz9, Minna Kohler10, josefina marin11, NZEUSSEU TOUKAP Adrien12, Marcos Rosemffet13, Ari Polachek14, Ernesto Rodriguez15, Ágnes Sarolta Szentpétery16, Abha Singh17, Maria S. Stoenoiu18, Ilaria Tinazzi19, Janeth Yinh10, Gurjit Kaeley20 and Sibel Aydin21, 1University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, 2FAMERP, São José do Rio Preto, Brazil, 3Women's College Hospital, Toronto, Canada, 4Intermountain Health Care, Salt Lake City, UT, 5UZ Gent, Gent, Belgium, 6Al Hada Forces Hospital, Rheumatology Department, Taif, Saudi Arabia, 7Carmel Medical Centre, Haifa, Israel, 8University of California San Diego, La Jolla, CA, 9GRAPPA - Patient Research Partner, Haifa, Israel, 10Massachusetts General Hospital, Boston, MA, 11Hospital Italiano de Buenos Aires, buenos aires, Argentina, 12Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, 13Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, 14Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel, 15Florida Medical Clinic, Tampa, FL, 16Uppsala University Hospital, Uppsala, Sweden, 17University of California, San Diego, San Diego, CA, 18Cliniques Universitaires Saint-Luc, Brussels, Belgium, 19Ospedale Sacro Cuore-Don Calabria, Verona, Italy, 20UF COM-J, Ponte Vedra Beach, FL, 21University of Ottawa - Ottawa, Ottawa, ON, Canada

Meeting: ACR Convergence 2024

Keywords: Imaging, Psoriatic arthritis, risk assessment, Spondyloarthropathies, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: Imaging of Rheumatic Diseases

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Enthesitis is a key domain in psoriatic arthritis (PsA). The Diagnostic Ultrasound Enthesitis Tool (DUET) study aims to develop a new PsA-specific sonographic scoring system for enthesitis, to assist with the diagnosis of PsA. We present a preliminary analysis examining the distribution of elementary ultrasound lesions in PsA and controls.

Methods: The DUET study prospectively enrolled patients with early PsA, psoriasis alone, and non-psoriatic controls in 17 centers. Participants underwent a standardized ultrasound exam protocol of 16 entheseal sites in the upper and lower extremities by local site sonographers. Subsequently, scans were evaluated by three central readers to derive a consensus score. Abnormalities were scored on a semi-quantitative scale for Inflammatory lesions: hypoechogenicity (0-1), thickening (0-1), Power Doppler (PD, 0-3); and Structural lesions: calcification (0-3), enthesophyte (0-3), Erosion (0-1). The differences in the distribution of lesions between PsA and controls were assessed using trend test.  

Results: We analyzed 213 patients with PsA (mean age 49.4±13.9, 51.2% female) and 106 controls (mean age 49.2±15.5, 58.5% female). The mean duration of PsA was 1.9±3.4. None of the participants received biologic/targeted-synthetic DMARD. Notably, 70% of PsA patients and 49% of controls exhibited tenderness in at least one enthesis.

While the prevalence of inflammatory elementary lesions was generally higher in PsA than in the controls, the variations across the two groups depended on the specific entheseal site (Figure 1). Particularly, pronounced differences were observed in the patellar tendon insertions to the patella and tibial tuberosity, Achilles and triceps tendon.

While generally infrequent, PD signal was notably higher in PsA patients, especially if detected in the presence of hypoechogenicity or thickening. Bone erosions were rare across most sites (Figure 2) and predominantly found in PsA cases. Exceptions are the supraspinatus insertions and lateral epicondyles, where erosions were more frequent, however comparable in PsA and controls. Enthesophytes were common in both PsA patients and controls, however, PsA patients had larger enthesophytes at the patellar tendon origins and insertions, Achilles, and supraspinatus than controls (Figure 3).

Conclusion: Sonographic entheseal abnormalities are not exclusive to PsA. Therefore, to distinguish PsA from controls, any sonographic scoring system should account not only for the presence of particular lesions but also for their severity and the precise entheseal site affected. This preliminary analysis will inform the next steps of developing a composite ultrasound score aimed at aiding in the diagnosis of PsA.

Supporting image 1

Figure 1: The distribution of Hypoechogenicty (1A. sum of left+right); Thickening (1B. sum of left+right), and Power Doppler (1C. prevalence in left+right) scores across entheseal sites. Cochrane-Armitage trend test of the difference in distribution between PsA and controls **p<0.05; *p<0.10. Ach- Achilles; Epi- Lateral epicondyle; Pat- Patellar tendon insertion to patella; Plan- Plantar fascia; Quad- Quadriceps; Sup- Supraspinatus; Tib- Patellar tendon insertion to tibia; Tric- Triceps.

Supporting image 2

Figure 2: The prevalence of erosions (left and/or right) across entheseal sites. Ach- Achilles; Epi- Lateral epicondyle; Pat- Patellar tendon insertion to patella; Plan- Plantar fascia; Quad- Quadriceps; Sup- Supraspinatus; Tib- Patellar tendon insertion to tibia; Tric- Triceps;

Supporting image 3

Figure 3: The distribution of enthesophyte scores (left+right) across entheseal sites. P value for Cochrane-Armitage trend test of the differences in distributions between PsA and controls. Ach- Achilles; Epi- Lateral epicondyle; Pat- Patellar tendon insertion to patella; Plan- Plantar fascia; Quad- Quadriceps; Sup- Supraspinatus; Tib- Patellar tendon insertion to tibia; Tric- Triceps;


Disclosures: L. Eder: AbbVie, 2, 5, 6, Bristol-Myers Squibb (BMS), 2, Eli Lilly, 2, 5, Fresenius Kabi, 5, Johnson & Johnson, 2, 5, Novartis, 1, 5, Pfizer, 5, 6, UCB, 5, 6; R. Acayaba de Toledo: AbbVie/Abbott, 5, 6, GlaxoSmithKlein(GSK), 5, 6, Janssen, 6, Novartis, 5, 6, UCB, 6; F. Afgani: None; C. Bakewell: AbbVie/Abbott, 2, 6, Eli Lilly, 2, 6, Janssen, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, Sanofi, 2, 6, UCB, 2, 6; P. Carron: None; B. Elnady: None; A. Haddad: None; A. Kavanaugh: AbbVie, 2, Amgen, 2, BMS, 2, Janssen, 2, MoonLake Immunotherapeutics, 2, Novartis, 2, Pfizer, 2, Takeda, 2, UCB, 2, 5; A. Katz: None; M. Kohler: Janssen, 12, medical advisory board, Novartis, 12, medical advisory board, Setpoint Medical, 5, Springer Publications, 9; j. marin: None; N. Adrien: None; M. Rosemffet: None; A. Polachek: None; E. Rodriguez: None; Á. Szentpétery: None; A. Singh: None; M. Stoenoiu: AbbVie/Abbott, 5, 6, Janssen, 5, 6, Novartis, 5, 6, Pfizer, 5, 6, Roche, 5, 6, Sanofi, 5, 6, UCB, 5, 6; I. Tinazzi: None; J. Yinh: None; G. Kaeley: AbbVie/Abbott, 5, Bristol-Myers Squibb(BMS), 5, Gilead, 5, Janssen, 5, Novartis, 5; S. Aydin: AbbVie/Abbott, 1, 2, 5, 6, Clarius, 11, Eli Lilly, 5, 6, Janssen, 1, 5, 6, Novartis, 1, 2, 5, 6, Pfizer, 1, 2, 5, 6, UCB, 1, 5, 6.

To cite this abstract in AMA style:

Eder L, Acayaba de Toledo R, Afgani F, Bakewell C, Carron P, Elnady B, Haddad A, Kavanaugh A, Katz A, Kohler M, marin j, Adrien N, Rosemffet M, Polachek A, Rodriguez E, Szentpétery Á, Singh A, Stoenoiu M, Tinazzi I, Yinh J, Kaeley G, Aydin S. Diagnostic Ultrasound Enthesitis Tool (DUET) for Psoriatic Arthritis: The Distribution of Elementary Lesions Is Influenced by Site [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/diagnostic-ultrasound-enthesitis-tool-duet-for-psoriatic-arthritis-the-distribution-of-elementary-lesions-is-influenced-by-site/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-ultrasound-enthesitis-tool-duet-for-psoriatic-arthritis-the-distribution-of-elementary-lesions-is-influenced-by-site/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology